's () chief executive Duncan Peyton talks to Proactive London's Katie Pilbeam about the clinical trial collaboration and supply agreement with Merck KGaA, and Inc.
Peyton says 'it's another step forward in how we work and expand our oncology franchise' which will begin with a clinical trial this year with BAVENCIO.
This is a drug for advanced or metastatic urothelial carcinoma (a form of bladder cancer) developed by Merck and Pfizer, in combination with UK group’s MRx0518.
Add related topics to MyProactive
Create your account: sign up and get ahead on news and events
NO INVESTMENT ADVICE
The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...
In exchange for publishing services rendered by the Company on behalf of 4D pharma PLC named herein, including the promotion by the Company of 4D pharma PLC in any Content on the Site, the Company receives from said...
FOR OUR FULL DISCLAIMER CLICK HERE
